Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 5, 2024
Emerging Company Profile
Tubulis: Enhancing ADC stability via new conjugation methods
German biotech raised series B2 round in March to push two highly stable ADC candidates into the clinic, and discover new payloads
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Mar 14, 2024
Finance
Venture Report: Tubulis’ big B round to advance ADCs, Relation adds to seed financing
Plus new rounds for Mission, Asgard and more
BioCentury | Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | May 20, 2022
Product Development
Next-gen NK cell enhancements in the clinic
Companies are turning to tumor targeting, IL-15 expression and alternate cell sourcing to boost the potency and longevity of NK cell therapies
BioCentury | May 3, 2022
Deals
Gilead’s $300M deal with Dragonfly builds on 2022’s NK cell momentum
Dragonfly attracts Gilead as fourth big biopharma partner
BioCentury | Jun 8, 2021
Product Development
With breast cancer readout for ADC, Dutch biotech Byondis aims for submission, seeks deal to finance pipeline
Byondis hopes a pivotal readout for its ADC to treat breast cancer will result in a transformational partnership that will allow the Dutch biotech to develop a pipeline with up to four more
BioCentury | Mar 26, 2021
Product Development
Next-generation checkpoint development surges as rare wins overshadow setbacks
Companies look to overcome challenges in next-generation checkpoints with new targets and modalities
BioCentury | Jun 11, 2020
Deals
In course correction, AbbVie steers toward innovation with Genmab deal
AbbVie reaffirms its commitment to cancer, paying $750M up front for rights to a trio of Genmab bispecifics
BioCentury | Feb 19, 2020
Finance
Feb. 19 Financial Quick Takes: bluebird's delayed BLA timeline, plus fundings for NeoTx, Scipher and EnClear
Items per page:
1 - 10 of 121